Eli Lilly and Company (LLY)
| Market Cap | 691.32B |
| Revenue (ttm) | 40.86B |
| Net Income (ttm) | 8.37B |
| Shares Out | 900.43M |
| EPS (ttm) | 9.25 |
| PE Ratio | 83.01 |
| Forward PE | 34.93 |
| Dividend | $6.00 (0.78%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 9,442,468 |
| Open | 811.35 |
| Previous Close | 757.54 |
| Day's Range | 766.61 - 811.35 |
| 52-Week Range | 567.42 - 972.53 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 963.64 (+25.51%) |
| Earnings Date | Feb 6, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the comp... [Read more]
Financial Performance
In 2023, Eli Lilly's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $963.64, which is an increase of 25.51% from the latest price.
News
Zepbound Approved For Sleep Apnea
The Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound approv...
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with...
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is now cle...
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated w...
Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture
The CNBC 'Halftime Report' Investment Committee discusses today's market movers.
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. Tirzepatide's clinical trial updates were very positive this year, including the...
Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert
SUGAR LAND, Texas--(BUSINESS WIRE)--Thanks largely to some blockbuster projects, the value of industrial construction presently underway in Indiana and tracked by Industrial Info exceeds $39 billion. ...
Novo Nordisk Stock Crashes 22% After Disappoitning Obesity Drug Data. Eli Lilly Shares Soar.
The experimental obesity drug CagriSema disappointed investors.
Focus: In weight loss battle, Novo and Lilly face growing offensive from licenced copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a threa...
US FDA says Lilly's weight-loss drug shortage resolved
The U.S. Food and Drug Administration said on Thursday that Eli Lilly's weight-loss drug shortage has been resolved, following a re-evaluation of the drug's supply by the agency.
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage
The Food and Drug Administration said the active ingredient in Eli Lilly's weight loss drug Zepbound is no longer in shortage, a decision that will eventually bar compounding pharmacies from making un...
Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook
Eli Lilly's diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide, support a "buy" rating for long-term investors despite current valuation metrics. Ze...
Scouting America Receives $30 million Grant from Lilly Endowment to Build Character in the Nation's Young People
IRVING, TX, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Scouting America, the nation's foremost youth program of character development and values-based leadership training, has been awarded a grant of $30 milli...
Merck's weight-loss pill deal: what it means for Eli Lilly
Merck & Co Inc (NYSE: MRK) is in focus this morning after announcing a $2.0 billion deal with Hansoh Pharma. The said agreement wins it rights to HS-10535 – an experimental weight-loss pill (oral) de...
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
BEIJING and BRIDGEWATER, N.J. , Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration ("...
Eli Lilly's Alzheimer's treatment approved in China
China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January, the company sa...
Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
China is the fourth major market where Kisunla has received approval Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in Oct...
Eli Lilly: A Rare Buying Opportunity
Eli Lilly's robust product portfolio, strategic acquisitions, and innovation-led initiatives drive its strong growth, positioning it well in the weight-loss, immunology, and oncology markets. LLY's ke...
Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
This milestone stems from the companies' collaboration to expand access to affordable insulin to one million people living with diabetes in low- to middle-income c ountries annually by 2030 INDIANAPOL...
Insurer stocks fall after Trump says 'we're going to knock out the middleman'
Shares of health insurers operating pharmacy benefit managers fell on Monday after U.S. President-elect Donald Trump called them middlemen who drive up costs and said he plans to eliminate their role.
Why the investor craze for Ozempic and rival weight-loss drugs may resume next year
Novo Nordisk's takeover of Catalent and the Danish firm's push to launch a new generation of drugs could boost the importance of GLP agonists in 2025, Barclays analysts said
Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China
SAN FRANCISCO and SUZHOU, China, Dec. 15, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ...
Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease
The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the positive opinion VIVID-1 was the first pivotal Crohn'...
EMA says Lilly's weight-loss drug does not need separate approval for sleep apnea
The European Medicines Agency said on Friday Eli Lilly's weight-loss drug does not need a separate approval for the treatment of a sleep disorder called obstructive sleep apnea (OSA).
Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market
Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker is gaining ground on its Europ...